Rosemary + Green Tea + Willow Infused Jojoba Oil + Squalane

At ORY^®, we believe you should know what’s in your products and why. This page lists the published research behind what we say about Rosemary + Green Tea + Willow Infused Jojoba Oil + Squalane. Each section starts with our claim, then tells you how well the research supports it, then lists the sources so you can read them yourself.

Please note: Some studies on this page tested rosemary, green tea and willow bark for medical conditions, including hair loss, and most used extracts, creams, or oral forms rather than an oil infusion. We share them for transparency. ORY^® infused oils are cosmetics and are not intended to treat any condition, grow hair, or prevent hair loss.

1. General Description and Role

Verification: Supported, with caveats. The Cosmetic Ingredient Review (CIR) Expert Panel has found these components safe in cosmetics: rosemary-derived ingredients are safe when formulated to be non-sensitizing; green tea leaf ingredients are safe when formulated to be non-sensitizing; jojoba oil is safe as used; squalane is safe as used. Willow-derived ingredients are still under CIR review, and the Panel has not reached a conclusion. CIR has not reviewed this specific blend.

Citations:

• • Cosmetic Ingredient Review Expert Panel. (2018). Safety assessment of Rosmarinus officinalis (rosemary)-derived ingredients as used in cosmetics. International Journal of Toxicology, 37(3 Suppl), 12S–50S. https://doi.org/10.1177/1091581818800020
    • What it shows: CIR safety assessment (Rosemary).
  • Cosmetic Ingredient Review Expert Panel. (2019). Safety assessment of Camellia sinensis-derived ingredients as used in cosmetics. International Journal of Toxicology, 38(3 Suppl), 48S–70S. https://doi.org/10.1177/1091581819889914
    • What it shows: CIR safety assessment (Green Tea).
  • Cosmetic Ingredient Review. (2026). Safety assessment of Salix alba (willow)-derived ingredients as used in cosmetics (Draft Tentative Report for the October 2026 Expert Panel meeting; Insufficient Data Announcement issued March 2026; no conclusion yet). https://www.cir-safety.org/sites/default/files/Willow.pdf
    • What it shows: CIR safety assessment (Willow Bark).
  • Cosmetic Ingredient Review. (1992). Final report on the safety assessment of jojoba oil and jojoba wax. Journal of the American College of Toxicology, 11(1), 57–74 (reaffirmed in a 2008 CIR report on jojoba-derived ingredients). https://doi.org/10.3109/10915819209141992
    • What it shows: CIR safety assessment (Jojoba Oil).
  • Elder, R. L. (Ed.). (1982). Final report on the safety assessment of squalane and squalene. Journal of the American College of Toxicology, 1(2), 37–56 (reaffirmed by CIR in 2003 and 2023). https://doi.org/10.1177/10915818231204276
    • What it shows: CIR safety assessment (Squalane).

2. Composition and Production

Verification: Supported. ORY^® steeps dried (never fresh) botanicals in the carrier, strains them out, and adds 0.5–1% vitamin E and 0.1% rosemary extract. An oil infusion captures mainly oil-soluble compounds, so its strength differs from the extracts used in research. ORY^® infused oils are made by steeping dried plant material in a carrier oil. The carrier oil makes up most of the finished product, so its own properties matter as much as the botanical’s — including allergy: nut-derived carrier oils such as sweet almond oil may not suit people with tree-nut allergies.

Citations:

• • Cosmetic Ingredient Review Expert Panel. (2018). Safety assessment of Rosmarinus officinalis (rosemary)-derived ingredients as used in cosmetics. International Journal of Toxicology, 37(3 Suppl), 12S–50S. https://doi.org/10.1177/1091581818800020
    • What it shows: Describes botanical composition.
  • Cosmetic Ingredient Review Expert Panel. (2019). Safety assessment of Camellia sinensis-derived ingredients as used in cosmetics. International Journal of Toxicology, 38(3 Suppl), 48S–70S. https://doi.org/10.1177/1091581819889914
    • What it shows: Describes botanical composition.
  • Cosmetic Ingredient Review. (2026). Safety assessment of Salix alba (willow)-derived ingredients as used in cosmetics (Draft Tentative Report for the October 2026 Expert Panel meeting; Insufficient Data Announcement issued March 2026; no conclusion yet). https://www.cir-safety.org/sites/default/files/Willow.pdf
    • What it shows: Describes botanical composition.
  • Cosmetic Ingredient Review. (1992). Final report on the safety assessment of jojoba oil and jojoba wax. Journal of the American College of Toxicology, 11(1), 57–74 (reaffirmed in a 2008 CIR report on jojoba-derived ingredients). https://doi.org/10.3109/10915819209141992
    • What it shows: Describes carrier composition.
  • Elder, R. L. (Ed.). (1982). Final report on the safety assessment of squalane and squalene. Journal of the American College of Toxicology, 1(2), 37–56 (reaffirmed by CIR in 2003 and 2023). https://doi.org/10.1177/10915818231204276
    • What it shows: Describes carrier composition.

3. Skin Type Suitability

Verification: Supported, with caveats. We found no clinical studies of this blend. Suitability is based on the carrier and the safety data for each ingredient.

Citations:

• • Cosmetic Ingredient Review. (1992). Final report on the safety assessment of jojoba oil and jojoba wax. Journal of the American College of Toxicology, 11(1), 57–74 (reaffirmed in a 2008 CIR report on jojoba-derived ingredients). https://doi.org/10.3109/10915819209141992
    • What it shows: Carrier safety data.
  • Elder, R. L. (Ed.). (1982). Final report on the safety assessment of squalane and squalene. Journal of the American College of Toxicology, 1(2), 37–56 (reaffirmed by CIR in 2003 and 2023). https://doi.org/10.1177/10915818231204276
    • What it shows: Carrier safety data.

4. Hair and Scalp Suitability

Verification: Limited evidence. A trial in people with androgenetic alopecia used rosemary essential oil, not a leaf infusion, and a mouse study used rosemary leaf extract. A lab study found EGCG stimulated cultured hair follicles. Salicylic acid is an FDA-regulated dandruff and acne drug ingredient; willow bark is not a substitute, and ORY^® does not make dandruff or acne claims for this oil. Hair-growth and hair-loss claims are drug claims, and ORY^® does not make them. ORY^® haircare products are not intended to treat dandruff or scalp conditions.

Citations:

• • Panahi, Y., Taghizadeh, M., Marzony, E. T., & Sahebkar, A. (2015). Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: A randomized comparative trial. SKINmed, 13(1), 15–21. https://pubmed.ncbi.nlm.nih.gov/25842469/
    • What it shows: Trial of rosemary essential oil in androgenetic alopecia (a medical use).
  • Murata, K., et al. (2013). Promotion of hair growth by Rosmarinus officinalis leaf extract. Phytotherapy Research, 27(2), 212–217. https://pubmed.ncbi.nlm.nih.gov/?term=Promotion%20of%20hair%20growth%20by%20Rosmarinus%20officinalis%20leaf%20extract
    • What it shows: Mouse study of rosemary leaf extract.
  • Kwon, O. S., et al. (2007). Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). Phytomedicine, 14(7–8), 551–555. https://pubmed.ncbi.nlm.nih.gov/17092697/
    • What it shows: Lab study of EGCG on hair follicles.
  • U.S. Food and Drug Administration. 21 CFR 310.527 — Drug products offered over-the-counter for external use as hair growers or for hair loss prevention. https://www.law.cornell.edu/cfr/text/21/310.527
    • What it shows: FDA treats hair-growth and hair-loss products as drugs.
  • U.S. Food and Drug Administration. 21 CFR Part 358, Subpart H — Drug products for the control of dandruff, seborrheic dermatitis, and psoriasis. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-358/subpart-H
    • What it shows: FDA dandruff drug rule (salicylic acid).

5. Benefits

Verification: Supported, with caveats. Most of the moisturizing benefit comes from the carrier. Rosemary’s antioxidant activity is well documented in lab studies. A study of citrus and rosemary extract taken by mouth does not apply to a topical oil. Human studies of green tea for sun protection and acne used water-soluble polyphenols or EGCG, not an oil infusion, and those are drug claims. Willow bark research has mostly studied extracts taken by mouth for pain. Salicin is converted to salicylic acid mainly after it is swallowed, so a willow bark infusion is not a substitute for salicylic acid. ORY^® does not make wound, eczema, acne, sun-protection, or hair-growth claims for this oil.

Citations:

• • Nieto, G., Ros, G., & Castillo, J. (2018). Antioxidant and antimicrobial properties of rosemary (Rosmarinus officinalis, L.): A review. Medicines, 5(3), 98. https://doi.org/10.3390/medicines5030098
    • What it shows: Review of rosemary.
  • Pérez-Sánchez, A., et al. (2014). Protective effects of citrus and rosemary extracts on UV-induced damage in skin cell model and human volunteers. Journal of Photochemistry and Photobiology B: Biology, 136, 12–18. https://pubmed.ncbi.nlm.nih.gov/24815058/
    • What it shows: Lab and oral human study.
  • Katiyar, S. K., Ahmad, N., & Mukhtar, H. (2000). Green tea and skin. Archives of Dermatology, 136(8), 989–994. https://doi.org/10.1001/archderm.136.8.989
    • What it shows: Review of green tea and skin.
  • Elmets, C. A., Singh, D., Tubesing, K., Matsui, M., Katiyar, S., & Mukhtar, H. (2001). Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. Journal of the American Academy of Dermatology, 44(3), 425–432. https://pubmed.ncbi.nlm.nih.gov/11209110/
    • What it shows: Human UV study (not an oil infusion).
  • Yoon, J. Y., Kwon, H. H., Min, S. U., Thiboutot, D. M., & Suh, D. H. (2013). Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. Journal of Investigative Dermatology, 133(2), 429–440. https://pubmed.ncbi.nlm.nih.gov/23096708/
    • What it shows: Acne study of EGCG (a medical use).
  • Shara, M., & Stohs, S. J. (2015). Efficacy and safety of white willow bark (Salix alba) extracts. Phytotherapy Research, 29(8), 1112–1116. https://doi.org/10.1002/ptr.5377
    • What it shows: Review of willow bark (mostly oral use).
  • Huang, Z. R., Lin, Y. K., & Fang, J. Y. (2009). Biological and pharmacological activities of squalene and related compounds: Potential uses in cosmetic dermatology. Molecules, 14(1), 540–554. https://www.mdpi.com/1420-3049/14/1/540
    • What it shows: Review of squalane.
  • U.S. Food and Drug Administration. (2019, February 26). Sunscreen drug products for over-the-counter human use (proposed rule), 84 FR 6204. https://www.federalregister.gov/documents/2019/02/26/2019-03019/sunscreen-drug-products-for-over-the-counter-human-use
    • What it shows: FDA sunscreen rules.
  • U.S. Food and Drug Administration. 21 CFR Part 333, Subpart D — Topical acne drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-333/subpart-D
    • What it shows: FDA acne drug rule.

6. Use Across ORY^® Product Lines

Verification: Supported. Soap use by carrier: Jojoba Oil — superfat only (2–5%); Squalane — does not saponify; superfat only (1–3%). Being oil-only, the infusion needs no preservative if kept free of water.

Citations:

• • Cosmetic Ingredient Review. (1992). Final report on the safety assessment of jojoba oil and jojoba wax. Journal of the American College of Toxicology, 11(1), 57–74 (reaffirmed in a 2008 CIR report on jojoba-derived ingredients). https://doi.org/10.3109/10915819209141992
    • What it shows: CIR safety assessment (Jojoba Oil).
  • Elder, R. L. (Ed.). (1982). Final report on the safety assessment of squalane and squalene. Journal of the American College of Toxicology, 1(2), 37–56 (reaffirmed by CIR in 2003 and 2023). https://doi.org/10.1177/10915818231204276
    • What it shows: CIR safety assessment (Squalane).
  • U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
    • What it shows: FDA explains how soap is regulated.

7. Pros

Verification: Supported, with caveats. Each component has a CIR safety conclusion except willow bark, which is still under review.

Citations:

• • Cosmetic Ingredient Review Expert Panel. (2018). Safety assessment of Rosmarinus officinalis (rosemary)-derived ingredients as used in cosmetics. International Journal of Toxicology, 37(3 Suppl), 12S–50S. https://doi.org/10.1177/1091581818800020
    • What it shows: CIR safety assessment (Rosemary).
  • Cosmetic Ingredient Review Expert Panel. (2019). Safety assessment of Camellia sinensis-derived ingredients as used in cosmetics. International Journal of Toxicology, 38(3 Suppl), 48S–70S. https://doi.org/10.1177/1091581819889914
    • What it shows: CIR safety assessment (Green Tea).
  • Cosmetic Ingredient Review. (2026). Safety assessment of Salix alba (willow)-derived ingredients as used in cosmetics (Draft Tentative Report for the October 2026 Expert Panel meeting; Insufficient Data Announcement issued March 2026; no conclusion yet). https://www.cir-safety.org/sites/default/files/Willow.pdf
    • What it shows: CIR safety assessment (Willow Bark).
  • Cosmetic Ingredient Review. (1992). Final report on the safety assessment of jojoba oil and jojoba wax. Journal of the American College of Toxicology, 11(1), 57–74 (reaffirmed in a 2008 CIR report on jojoba-derived ingredients). https://doi.org/10.3109/10915819209141992
    • What it shows: CIR safety assessment (Jojoba Oil).
  • Elder, R. L. (Ed.). (1982). Final report on the safety assessment of squalane and squalene. Journal of the American College of Toxicology, 1(2), 37–56 (reaffirmed by CIR in 2003 and 2023). https://doi.org/10.1177/10915818231204276
    • What it shows: CIR safety assessment (Squalane).

8. Cons

Verification: Supported. We list these limits so you have the full picture:

• • Variable strength. Depends on botanical quality, ratio, and steeping time.
  • Different forms in research. Studies used extracts, creams, essential oils, or oral products, not this infusion.
  • Partial capture. Oil captures only part of green tea’s water-soluble catechins.
  • Willow bark. Contains salicylates and is still under CIR review.
  • Camphor. Rosemary leaf contains small amounts of camphor and 1,8-cineole.
  • No blend-specific trials. Evidence is for individual ingredients.

Citations:

• • Nieto, G., Ros, G., & Castillo, J. (2018). Antioxidant and antimicrobial properties of rosemary (Rosmarinus officinalis, L.): A review. Medicines, 5(3), 98. https://doi.org/10.3390/medicines5030098
    • What it shows: Review of rosemary.
  • Pérez-Sánchez, A., et al. (2014). Protective effects of citrus and rosemary extracts on UV-induced damage in skin cell model and human volunteers. Journal of Photochemistry and Photobiology B: Biology, 136, 12–18. https://pubmed.ncbi.nlm.nih.gov/24815058/
    • What it shows: Lab and oral human study.

9. Safety Notes

Verification: Supported. Follow these precautions:

• • Patch test any new product on a small area for 24–48 hours before full use.
  • Willow bark contains salicylates. Do not use if you are allergic to aspirin or other salicylates.
  • Rosemary contains camphor. If you have epilepsy or a seizure disorder, ask a healthcare provider before use.
  • If you have a nut or seed allergy, check the carrier before use.
  • Store away from heat and light, keep water out of the bottle, and discard if it smells rancid.
  • Stop use if redness, burning, itching, or rash occurs, and talk to a healthcare provider.
  • For external use only. Avoid the eyes.
  • If you are pregnant, nursing, have a medical condition, or are buying for a child, ask a healthcare provider before use.

Citations:

• • Cosmetic Ingredient Review. (1992). Final report on the safety assessment of jojoba oil and jojoba wax. Journal of the American College of Toxicology, 11(1), 57–74 (reaffirmed in a 2008 CIR report on jojoba-derived ingredients). https://doi.org/10.3109/10915819209141992
    • What it shows: Carrier safety.
  • Elder, R. L. (Ed.). (1982). Final report on the safety assessment of squalane and squalene. Journal of the American College of Toxicology, 1(2), 37–56 (reaffirmed by CIR in 2003 and 2023). https://doi.org/10.1177/10915818231204276
    • What it shows: Carrier safety.

10. Product-line notes

• • ORY^® Skincare: For external use only. Not for deep or puncture wounds, animal bites, or serious burns.
  • ORY^® Haircare: Designed for scalp comfort and the look and feel of hair. Not intended to treat dandruff or scalp conditions, or to promote hair growth or prevent hair loss. If you notice sudden shedding or a persistent itchy, flaking scalp, see a dermatologist.
  • ORY^® Handmade Soap: Handmade soap is naturally alkaline, and each bar may vary slightly in color, scent, and texture. Not intended to treat eczema or any skin condition.
  • ORY^® Cosmetics: Lip products are not intended to treat or protect chapped or cracked lips. Do not share applicators, and replace any product that changes color, smell, or texture.

11. References

Peer-reviewed research

• • Cosmetic Ingredient Review Expert Panel. (2018). Safety assessment of Rosmarinus officinalis (rosemary)-derived ingredients as used in cosmetics. International Journal of Toxicology, 37(3 Suppl), 12S–50S. https://doi.org/10.1177/1091581818800020
  • Cosmetic Ingredient Review Expert Panel. (2019). Safety assessment of Camellia sinensis-derived ingredients as used in cosmetics. International Journal of Toxicology, 38(3 Suppl), 48S–70S. https://doi.org/10.1177/1091581819889914
  • Cosmetic Ingredient Review. (1992). Final report on the safety assessment of jojoba oil and jojoba wax. Journal of the American College of Toxicology, 11(1), 57–74 (reaffirmed in a 2008 CIR report on jojoba-derived ingredients). https://doi.org/10.3109/10915819209141992
  • Cosmetic Ingredient Review. (2026). Safety assessment of Salix alba (willow)-derived ingredients as used in cosmetics (Draft Tentative Report for the October 2026 Expert Panel meeting; Insufficient Data Announcement issued March 2026; no conclusion yet). https://www.cir-safety.org/sites/default/files/Willow.pdf
  • Elder, R. L. (Ed.). (1982). Final report on the safety assessment of squalane and squalene. Journal of the American College of Toxicology, 1(2), 37–56 (reaffirmed by CIR in 2003 and 2023). https://doi.org/10.1177/10915818231204276
  • Elmets, C. A., Singh, D., Tubesing, K., Matsui, M., Katiyar, S., & Mukhtar, H. (2001). Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. Journal of the American Academy of Dermatology, 44(3), 425–432. https://pubmed.ncbi.nlm.nih.gov/11209110/
  • Huang, Z. R., Lin, Y. K., & Fang, J. Y. (2009). Biological and pharmacological activities of squalene and related compounds: Potential uses in cosmetic dermatology. Molecules, 14(1), 540–554. https://www.mdpi.com/1420-3049/14/1/540
  • Katiyar, S. K., Ahmad, N., & Mukhtar, H. (2000). Green tea and skin. Archives of Dermatology, 136(8), 989–994. https://doi.org/10.1001/archderm.136.8.989
  • Kwon, O. S., et al. (2007). Human hair growth enhancement in vitro by green tea epigallocatechin-3-gallate (EGCG). Phytomedicine, 14(7–8), 551–555. https://pubmed.ncbi.nlm.nih.gov/17092697/
  • Murata, K., et al. (2013). Promotion of hair growth by Rosmarinus officinalis leaf extract. Phytotherapy Research, 27(2), 212–217. https://pubmed.ncbi.nlm.nih.gov/?term=Promotion%20of%20hair%20growth%20by%20Rosmarinus%20officinalis%20leaf%20extract
  • Nieto, G., Ros, G., & Castillo, J. (2018). Antioxidant and antimicrobial properties of rosemary (Rosmarinus officinalis, L.): A review. Medicines, 5(3), 98. https://doi.org/10.3390/medicines5030098
  • Panahi, Y., Taghizadeh, M., Marzony, E. T., & Sahebkar, A. (2015). Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: A randomized comparative trial. SKINmed, 13(1), 15–21. https://pubmed.ncbi.nlm.nih.gov/25842469/
  • Pérez-Sánchez, A., et al. (2014). Protective effects of citrus and rosemary extracts on UV-induced damage in skin cell model and human volunteers. Journal of Photochemistry and Photobiology B: Biology, 136, 12–18. https://pubmed.ncbi.nlm.nih.gov/24815058/
  • Shara, M., & Stohs, S. J. (2015). Efficacy and safety of white willow bark (Salix alba) extracts. Phytotherapy Research, 29(8), 1112–1116. https://doi.org/10.1002/ptr.5377
  • Yoon, J. Y., Kwon, H. H., Min, S. U., Thiboutot, D. M., & Suh, D. H. (2013). Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. Journal of Investigative Dermatology, 133(2), 429–440. https://pubmed.ncbi.nlm.nih.gov/23096708/

Government and regulatory sources

• • U.S. Food and Drug Administration. 21 CFR 310.527 — Drug products offered over-the-counter for external use as hair growers or for hair loss prevention. https://www.law.cornell.edu/cfr/text/21/310.527
  • U.S. Food and Drug Administration. (2019, February 26). Sunscreen drug products for over-the-counter human use (proposed rule), 84 FR 6204. https://www.federalregister.gov/documents/2019/02/26/2019-03019/sunscreen-drug-products-for-over-the-counter-human-use
  • U.S. Food and Drug Administration. 21 CFR Part 333, Subpart D — Topical acne drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-333/subpart-D
  • U.S. Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
  • U.S. Food and Drug Administration. 21 CFR Part 358, Subpart H — Drug products for the control of dandruff, seborrheic dermatitis, and psoriasis. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-358/subpart-H